Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes
Sihui Luo,Xueying Zheng,Wei Bao,Sheng Nie,Yu Ding,Tong Yue,Yilun Zhou,Ying Hu,Hua Li,Qiongqiong Yang,Qijun Wan,Bicheng Liu,Hong Xu,Guisen Li,Gang Xu,Chunbo Chen,Huafeng Liu,Yongjun Shi,Yan Zha,Yaozhong Kong,Guobin Su,Ying Tang,Mengchun Gong,Linong Ji,Fan Fan Hou,Jianping Weng
DOI: https://doi.org/10.1038/s41392-024-01854-9
IF: 39.3
2024-06-07
Signal Transduction and Targeted Therapy
Abstract:Early insulin therapy is capable to achieve glycemic control and restore β-cell function in newly diagnosed type 2 diabetes (T2D), but its effect on cardiovascular outcomes in these patients remains unclear. In this nationwide real-world study, we analyzed electronic health record data from 19 medical centers across China between 1 January 2000, and 26 May 2022. We included 5424 eligible patients (mean age 56 years, 2176 women/3248 men) who were diagnosed T2D within six months and did not have prior cardiovascular disease. Multivariable Cox regression models were used to estimate the associations of early insulin therapy (defined as the first-line therapy for at least two weeks in newly diagnosed T2D patients) with the incidence of major cardiovascular events including coronary heart disease (CHD), stroke, and hospitalization for heart failure (HF). During 17,158 persons years of observation, we documented 834 incident CHD cases, 719 stroke cases, and 230 hospitalized cases for HF. Newly diagnosed T2D patients who received early insulin therapy, compared with those who did not receive such treatment, had 31% lower risk of incident stroke, and 28% lower risk of hospitalization for HF. No significant difference in the risk of CHD was observed. We found similar results when repeating the aforesaid analysis in a propensity-score matched population of 4578 patients and with inverse probability of treatment weighting models. These findings suggest that early insulin therapy in newly diagnosed T2D may have cardiovascular benefits by reducing the risk of incident stroke and hospitalization for HF.
biochemistry & molecular biology,cell biology